News & Updates

A weak innate immunity appears to play a central role in severe infections of the coronavirus disease 2019 (COVID-19), a recent study has found.

Treatment with the selective serotonin reuptake inhibitor fluvoxamine may prevent hospitalization in outpatients presenting with symptoms of COVID-19 who have a high risk for disease progression, according to results of the TOGETHER trial.

Use of atorvastatin in adults with COVID-19 admitted to the intensive care unit (ICU) is safe but does not result in a marked decrease in the composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all-cause mortality, a study has shown.

Vaccines against the coronavirus disease 2019 (COVID-19) often cause temporary disturbances in cardiovascular, respiratory, and sleep physiology, according to a new study. Moreover, such perturbations can be detected by wearable devices.

Bacteraemic pneumococcal community-acquired pneumonia is associated with higher disease severity and frequent intensive care unit admission, as reported in a study. However, SARS-CoV-2-related pneumonia poses a greater mortality risk.

Among patients with Mycobacterium avium complex pulmonary disease, the risk of chronic pulmonary aspergillosis development and mortality is high in the presence of emphysema, according to a study.

There appears to be a higher prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19 than previously reported, reveals a recent study.

The memory B cell response appears to be weaker in vaccinated individuals who develop breakthrough infections with the Delta variant of the coronavirus disease 2019 (COVID-19), according to a new Singapore study.